ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.99
0.00%
US Tech 100
19,795.60
-0.43%
S&P 500
5,849.72
-1.76%
US Dollar vs CAD
1.44143
-0.54%
Bitcoin
83,510.83
-2.99%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE

  6. Arcus Biosciences Inc (RCUS) Share Price

Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS)

NYSE
10.50
-0.39
(-3.58%)
Closed March 03 3:00PM
Delayed by 15 minutes
10.44
-0.06
( -0.57% )
Pre Market: 6:01AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
10.44
Bid
-
Ask
-
Volume
449
0.00 Day's Range 0.00
9.24 52 Week Range 19.688
Market Cap
1.105B
Previous Close
10.50
Open
-
Last Trade
100
@
10.44
(formt)
Last Trade Time
06:01:01
Financial Volume
-
VWAP
-
Average Volume (3m)
880,700
Shares Outstanding
105,841,422
Dividend Yield
-
PE Ratio
-3.62
Earnings Per Share (EPS)
-2.9
Revenue
117M
Net Profit
-307M

About Arcus Biosciences Inc

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.arcusbio.com
Headquarters
Camden, Delaware, USA
Founded
-
Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was US$10.50. Over the last year, Arcus Biosciences shares have traded in a share price range of US$ 9.24 to US$ 19.688.

Arcus Biosciences currently has 105,841,422 shares outstanding. The market capitalization of Arcus Biosciences is US$1.11 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -3.62.

Ask ADVFN Intelligence (AI)

RCUS Latest News

More News

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
February 25 2025
RCUS (-3.58%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
February 25 2025
RCUS (-3.58%)

Form 8-K - Current report
Edgar (US Regulatory)
February 25 2025
RCUS (-3.58%)

Form 8-K - Current report
Edgar (US Regulatory)
February 19 2025
RCUS (-3.58%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
February 18 2025
RCUS (-3.58%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.232.2526934378110.2111.689.24137123410.36817336CS
4-2.77-20.968962906913.2113.89.24132816511.15474851CS
12-6.72-39.160839160817.1618.079.2488070012.88172321CS
26-6.13-36.994568497316.5718.989.2478664314.72444468CS
52-8.92-46.074380165319.3619.6889.2472228415.48415749CS
156-25.23-70.731707317135.6739.759.2488488820.40427309CS
260-7.08-40.410958904117.5249.19.2477266223.44035732CS

RCUS - Frequently Asked Questions (FAQ)

What is the current Arcus Biosciences share price?
The current share price of Arcus Biosciences is US$ 10.44
How many Arcus Biosciences shares are in issue?
Arcus Biosciences has 105,841,422 shares in issue
What is the market cap of Arcus Biosciences?
The market capitalisation of Arcus Biosciences is USD 1.11B
What is the 1 year trading range for Arcus Biosciences share price?
Arcus Biosciences has traded in the range of US$ 9.24 to US$ 19.688 during the past year
What is the PE ratio of Arcus Biosciences?
The price to earnings ratio of Arcus Biosciences is -3.62
What is the cash to sales ratio of Arcus Biosciences?
The cash to sales ratio of Arcus Biosciences is 9.5
What is the reporting currency for Arcus Biosciences?
Arcus Biosciences reports financial results in USD
What is the latest annual turnover for Arcus Biosciences?
The latest annual turnover of Arcus Biosciences is USD 117M
What is the latest annual profit for Arcus Biosciences?
The latest annual profit of Arcus Biosciences is USD -307M
What is the registered address of Arcus Biosciences?
The registered address for Arcus Biosciences is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
What is the Arcus Biosciences website address?
The website address for Arcus Biosciences is www.arcusbio.com
Which industry sector does Arcus Biosciences operate in?
Arcus Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SPHRSphere Entertainment Co
US$ 47.99
(27.33%)
56
KNKnowles Corporation
US$ 19.99
(25.41%)
273
UISUnisys Corporation New
US$ 5.19
(23.28%)
10
ALURAllurion Technologies Inc
US$ 3.32
(16.49%)
176
ALAir Lease Corporation
US$ 51.99
(13.10%)
13
KRMNKarman Holdings Inc
US$ 29.00
(-13.25%)
59
BODIBeachbody Company Inc
US$ 6.86
(-12.94%)
4
EBSEmergent Biosolutions Inc
US$ 6.00
(-12.15%)
9.43k
GRDNGuardian Pharmacy Services Inc
US$ 16.64
(-12.00%)
12
SESSES AI Corporation
US$ 0.5075
(-11.48%)
302.43k
IONQIonQ Inc
US$ 22.75
(-1.56%)
654.12k
QBTSD Wave Quantum Inc
US$ 4.67
(-4.69%)
567.03k
BBAIBigBear ai Holdings Inc
US$ 4.65
(-2.31%)
473.8k
BCSBarclays PLC
US$ 15.34
(-3.10%)
414.81k
TGTTarget Corp
US$ 121.35
(0.49%)
351.73k

RCUS Discussion

View Posts
Monksdream Monksdream 6 months ago
RCUS a buy under $14
👍️0
PennyWorld PennyWorld 2 years ago
https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
👍️0
conix conix 3 years ago
Biotechs are starting to react to news...finally.
👍️0
dinogreeves dinogreeves 5 years ago
The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
👍️0
lovetc lovetc 5 years ago
Also in the DEF 14.....didnt see any information regarding Gilead....
👍️0
lovetc lovetc 5 years ago
shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
👍️0
dinogreeves dinogreeves 5 years ago
RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
👍️0
dinogreeves dinogreeves 5 years ago
Bought another 1000 shares on that dip, going to wait this one.
👍️0
dinogreeves dinogreeves 5 years ago
Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
👍️0
dinogreeves dinogreeves 5 years ago
RCUS getting ready to pop to 33-35 dollars.
👍️0
dinogreeves dinogreeves 5 years ago
This is my letter to the shorts with margin account


That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 years ago
News could come from GI*LD that there is a buyout. Watch for news.
👍️0

Your Recent History

NYSE
RCUS
Arcus Biosciences
NASDAQ
AEMD
Aethlon Medical
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads